相关实验视频
Updated: Feb 23, 2026

10:36
Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
20.9K
使用益生菌预防反复的自发早产:来自前性,单臂,多中心试验的结果
Satoshi Yoneda1, Nobuko Akamata2, Manabu Nakamura3
1Department of Obstetrics and Gynecology, University of Toyama, Toyama, Japan.
American journal of obstetrics and gynecology
|February 21, 2026
概括
口服益生菌显著降低了高风险妇女的复发性自发早产 (sPTD). 这种干预提供了一种有希望的策略,可以降低sPTD的发病率并改善妊娠结果.
科学领域:
- 产科和妇科 产科和妇科
- 微生物组研究 微生物组研究
- 孕产妇和胎儿医学 孕产妇和胎儿医学
背景情况:
- 经常性自发早产 (sPTD) 影响全球30%和日本22.3%,带来重大风险.
- 益生菌,特别是Clostridium物种,可以通过调节维持怀孕至关重要的调节性T细胞来预防sPTD.
研究的目的:
- 研究口服益生菌 (包括Clostridium butyricum) 在预防高风险孕妇中复发性sPTD的疗效.
主要方法:
- 一项前性,单臂,多中心试验,涉及315名高风险孕妇,从怀孕10-14周到36周6天接受口服益生菌.
- 主要终点是<37周的sPTD复发率,相比之下,日本的历史全国率为22.3%.
主要成果:
- 在<37周的sPTD复发率为14.9%,明显低于历史的复发率 (p=0.0013).
- 在34周前的sPTD率为3.5%,在28周前的复发sPTD率为1.5%,在有极端早产史的妇女中.
- 没有报告死亡出生或严重不良事件.
结论:
- 与历史国家数据相比,口服益生菌与复发性sPTD的减少率有关.
- 这种益生菌方法显示了减少复发性sPTD的潜力,并保证了对受控试验的进一步调查.
相关概念视频
Healthcare Associated Infections II: Preventive Measures
4.4K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.4K
Intrauterine Drug Delivery Systems
41
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
41
Drugs for Treatment of Constipation-Predominant IBS
943
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
943
Drugs for Treatment of Diarrhea-Predominant IBS
781
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
781
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K

